Regeneron Pharmaceuticals Q3 Adj. EPS $20.07 Beats $16.19 Estimate, Sales $5.116B Beat $4.542B Estimate
Benzinga Newsdesk 2 days ago
NewsEarningsHotEarnings Beats
Regeneron Pharmaceuticals (NASDAQ:REGN) reported quarterly earnings of $20.07 per share which beat the analyst consensus estimate of $16.19 by 23.97 percent. This is a 69.65 percent increase over earnings of $11.83 per
Regeneron Pharmaceuticals (NASDAQ:REGN) reported quarterly earnings of $20.07 per share which beat the analyst consensus estimate of $16.19 by 23.97 percent. This is a 69.65 percent increase over earnings of $11.83 per share from the same period last year. The company reported quarterly sales of $5.116 billion which beat the analyst consensus estimate of $4.542 billion by 12.64 percent. This is a 36.28 percent increase over sales of $3.754 billion the same period last year.